AtriCure, Inc. (ATRC)

Check out top investors' recommendation for ATRC
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
38.33
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
AtriCure, Inc., a medical device company, develops, manufactures, and sells cardiac surgical ablation systems designed to create precise lesions or scars in cardiac tissue. It provides isolator bipolar radio-frequency ablation clamps that are used for ablation during open-heart procedures; and ablation and sensing unit, a compact power generator that provides the radio-frequency (RF) energy for its clamps, multifunctional pens, and coolrail linear ablation devices. The company also offers AtriCure switch box, a compact switch box, which offers the technology needed for the dual pulsing electrodes in isolator synergy clamps; isolator multifunctional pens that enable surgeons to evaluate cardiac arrhythmias, as well as to perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and coolrail linear ablation device, a disposable linear RF ablation device that allows physicians to create an expanded cardiac ablation lesion set during minimally invasive procedures. In addition, it provides cryoablation system, which is used for AF ablation treatment during certain open-heart procedures; and AtriClip System that is designed to exclude the left atrial appendage by implanting the device during concomitant open surgical procedures. Further, the company sells technologies, including Lumitip dissector to separate tissues to provide access to anatomical structures that are targeted for ablation; and the MicroPace ORLab system, a stimulating, mapping, and recording system, which enables physicians to confirm that the ablation lines being created are forming electrical barriers or lines of block. The company sells its products to hospitals and medical centers through independent distributors and direct sales personnel worldwide. AtriCure, Inc. is headquartered in West Chester, Ohio.
Sector:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Matthew O'Brien William Blair & Company, L.L.C. Buy   Oct 11, '18     36.00  Oct 11, '19  N/A 
Jason Mills Canaccord Genuity Buy   Oct 09, '18     40.00  Oct 09, '19  N/A 
Michael Matson Mizuho Securities USA Buy   Oct 04, '18     39.00  Oct 04, '19  N/A 
Suraj Kalia Northland Sec Buy   Aug 02, '18     30.00  Aug 02, '19  N/A 
Rick Wise Stifel Nicolaus & Company, Inc. Buy   Aug 02, '18     34.00  Aug 02, '19  N/A 
Jason Mills Canaccord Genuity Buy   Aug 02, '18     37.00  Aug 02, '19  N/A 
Jason Mills Canaccord Genuity Buy   Jun 27, '18     35.00  Jun 27, '19  N/A 
Rick Wise Stifel Nicolaus & Company, Inc. Buy   Jun 27, '18     32.00  Jun 27, '19  N/A 
Matthew O'Brien William Blair & Company, L.L.C. Buy   Jun 26, '18     30.00  Jun 26, '19  N/A 
Michael Matson Mizuho Securities USA Buy   Jun 18, '18     32.00  Jun 18, '19  N/A 
Matthew O'Brien William Blair & Company, L.L.C. Buy   Mar 13, '18     24.00  Mar 13, '19  N/A 
Suraj Kalia Northland Sec Buy   Feb 27, '18     25.00  Feb 27, '19  N/A 
Jason Mills Canaccord Genuity Buy   Feb 27, '18     26.00  Feb 27, '19  N/A 
Michael Matson Mizuho Securities USA Buy   Feb 27, '18     23.00  Feb 27, '19  N/A 
Michael Matson Mizuho Securities USA Buy   Jan 16, '18     23.00  Jan 16, '19  N/A 
Suraj Kalia Northland Sec Buy   Jan 16, '18     25.00  Jan 16, '19  N/A 
Jason Mills Canaccord Genuity Buy   Jan 08, '18     24.00  Jan 08, '19  N/A 
Matthew O'Brien William Blair & Company, L.L.C. Buy   Dec 10, '17     24.00  Dec 10, '18  N/A 
Suraj Kalia Northland Sec Buy   Nov 02, '17     25.00  Nov 02, '18  N/A 
Michael Matson Mizuho Securities USA Buy   Nov 02, '17     25.00  Nov 02, '18  N/A 
< previous123